e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
March 24, 2008
Date of Report (Date of earliest event reported)
 
 
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware   000-28782   93-0979187
(State or other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification Number)
     
157 Technology Drive    
Irvine, California   92618
(Address of principal executive offices)   (Zip Code)
(949) 788-6700
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
   
 
 

 

TABLE OF CONTENTS

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
SIGNATURES

Table of Contents

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     On March 24, 2008, the Compensation Committee of the Board of Directors of Spectrum Pharmaceuticals, Inc. (the “Company”) approved fiscal 2007 bonus payments for the Company’s named executive officers, as set forth below in the following table:
         
Name   Fiscal 2007 Bonus
Rajesh Shrotriya, Chairman, Chief Executive Officer and President
   $ 225,000  
Luigi Lenaz, Chief Scientific Officer
   $ 60,000  
Shyam Kumaria, Vice President, Finance
   $ 35,000  

 

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 27, 2008  
         
  SPECTRUM PHARMACEUTICALS, INC.
 		  
  By:   /s/ Shyam Kumaria    
  Name:  Shyam Kumaria   
  Title:  V.P., Finance